PTC Therapeutics (NASDAQ:PTCT) & GeoVax Labs (NASDAQ:GOVX) Head to Head Contrast

GeoVax Labs (NASDAQ:GOVX – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

6.1% of GeoVax Labs shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for GeoVax Labs and PTC Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeoVax Labs 1 1 1 0 2.00
PTC Therapeutics 1 3 10 1 2.73

GeoVax Labs currently has a consensus price target of $3,600.00, suggesting a potential upside of 178,117.82%. PTC Therapeutics has a consensus price target of $99.23, suggesting a potential upside of 62.75%. Given GeoVax Labs’ higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than PTC Therapeutics.

Valuation and Earnings

This table compares GeoVax Labs and PTC Therapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GeoVax Labs $2.49 million 0.41 -$21.47 million ($11.34) -0.18
PTC Therapeutics $1.73 billion 2.94 $682.64 million ($1.40) -43.55

PTC Therapeutics has higher revenue and earnings than GeoVax Labs. PTC Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GeoVax Labs and PTC Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GeoVax Labs N/A -901.14% -392.27%
PTC Therapeutics -9.17% N/A -0.10%

Volatility & Risk

GeoVax Labs has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Summary

PTC Therapeutics beats GeoVax Labs on 10 of the 15 factors compared between the two stocks.

About GeoVax Labs

(Get Free Report)

GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based in part on modified vaccinia Ankara (MVA), a viral-vector platform designed to prompt immune responses, including through the presentation of virus-like particles. Its vaccine pipeline includes GEO-CM04S1, an investigational COVID-19 vaccine being studied in clinical trials, as well as programs targeting other infectious diseases. GeoVax also develops Gedeptin, an investigational cancer therapy designed to make tumor cells more susceptible to treatment.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.